ALNYLAM PHARMACEUTICALS, INC. (ALNY) insider trading

By person

20 insiders · 0 transactions

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

Yvonne Greenstreet

Chief Executive Officer

—

96,209

$21.83M

+30.3%

Jeffrey Poulton V.

EVP, Chief Financial Officer

—

61,805

$14.02M

+113.9%

Tolga Tanguler

EVP, Chief Commercial Officer

—

34,297

$7.78M

+194.1%

Amy W Schulman

Director

—

24,049

$5.46M

+185.1%

Kevin Joseph Fitzgerald

CSO & EVP, Head of Research

—

20,569

$4.67M

+59.7%

Pushkal Garg

EVP Chief R&D

—

18,693

$4.24M

+19.0%

Michael W Bonney

Director

—

16,804

$3.81M

+4.8%

Bryan Supran

EVP, CLO and Secretary

—

12,807

$2.91M

—

Melissa McLaughlin

Chief Human Resources Officer

—

9,443

$2.14M

−29.3%

Robert W. Hesslein

EVP, CLO and Secretary

—

8,002

$1.82M

+10.4%

David E I Pyott

Director

—

1,582

$358.92K

+1,063%

Margaret A Hamburg

Director

—

1,582

$358.92K

+1,063%

Dennis A Ausiello

Director

—

1,582

$358.92K

+1,063%

Olivier Brandicourt

Director

—

1,446

$328.07K

—

Charles Elliott Sigal

Director

—

1,446

$328.07K

—

Colleen F Reitan

Director

—

1,446

$328.07K

+3,917%

Peter N Kellogg

Director

—

1,446

$328.07K

—

Carolyn R Bertozzi

Director

—

775

$175.83K

—

Stuart A Arbuckle

Director

—

671

$152.24K

—

Phillip A Sharp

Director

—

$0.00

—

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

ALNYLAM PHARMACEUTICALS, INC.

What the insiders did No buying or selling

By person